ESSA Pharma (EPIX) - 2025 Q2 - Quarterly Results

Exhibit 99.1 ESSA Pharma Reports Financial Results for Fiscal Second Quarter Ended March 31, 2025 Company continues to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, May 8, 2025 - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, had been focused on developing novel therapies for the treatment of prostate c ...